CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc., which trades under the original SPAC ticker PBAX on Nasdaq, is the product of Phoenix Biotech Acquisition Corp's de-SPAC merger with Cero Therapeutics, a clinical-stage oncology company focused on engineered chimeric antigen receptor T-cell therapies. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, completed its IPO in 2021 targeting the life sciences and biotechnology sector. The company filed this 8-K on October 14, 2025, reflecting its status as a post-combination operating entity in the oncology therapeutics space. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on PBAX and hundreds of other transactions.